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1150 Abstracts October 2013Table. Multivariate model: Vascular 30-day readmissions
Covariate OR 95% CI P valueBlack/African American (ref ¼ white) 1.21 1.04-1.41 .014
Procedure (ref ¼ carotid) Ref Ref <.001
EVAR 1.06 0.85-1.32 .616
Open AAA 1.53 1.18-1.98 .001
Other 1.49 1.24-1.80 <.001
Peripheral 1.93 1.59-2.34 <.001
Amputation 1.24 0.99-1.53 .057
Disposition (reference ¼ home) Ref Ref <.001
Nursing facility (prior) 1.54 1.13-2.10 .007
Facility/rehab (new) 1.30 1.12-1.50 <.001
Hypoalbuminemia 1.35 1.18-1.55 <.001
Pulmonary comorbidity 1.35 1.17-1.56 <.001
Cardiac comorbidity 1.28 1.13-1.44 <.001
Renal comorbidity 1.24 1.02-1.50 .033
VTE prior to discharge 1.83 1.00-3.36 .050
Graft failure prior to discharge 2.07 1.03-4.134 .040Scientiﬁc Session III: Peripheral
Risk Factors for Below-the-Knee Amputation Failure Requiring
Above-the-Knee Revision
Wadi Gomero-Cure, John J. Ricotta, Susanna Shin, Fred Beavers, Cameron
Akbari, Paul Foley. Washington Hospital Center, D.C
Objectives: The purpose of this study was to identify risk factors that
impact below-the-knee (BKA) failures requiring proximal revision to an
above-the-knee amputation (AKA).
Methods: All consecutive major lower extremity amputations or revi-
sions in vascular patients between 2009 and 2010 were identiﬁed. Medical
records were retrospectively reviewed for patient demographics, comorbid-
ities, amputation level, wound-healing, survival, and anatomic data (from
angiography and duplex examinations). Patients who healed their BKA
were compared with those requiring a proximal revision to an AKA. Statistical
analysis was performed with SAS System 9.1.3 (SAS Institute Inc, Cary, NC).
Results: Major lower extremity amputations or revisions were per-
formed on 247 limbs in 218 patients (age 66.7 6 12.2 years, 51% male,
87% African American). BKA was performed on 157 limbs (64%) with heal-
ing achieved in 114 (73%) and failure to heal in 42 (27%), of which 26 BKAs
(17%) required revision to an AKA. Women (58% vs 35%; P < .05), patients
with rest pain (15.4% vs 2.8%; P < .05), history of cardiac intervention or
surgery (50% vs 27%; P < .05), lower pre-albumin (9.3 6 2.5 mg/dL vs
13.1 6 7.8 mg/dL; P < .05) and patients with dementia (19.2% vs 6.4%;
P < .05) were more likely to require BKA to AKA revision. Preoperative
angiographic data was available for 69 (60%) of the healed BKAs and 17
(65%) of the BKA to AKA revisions. Ipsilateral common iliac artery stenosis
greater than 50% (18% vs 1.5%; P < .05), superﬁcial femoral artery occlusion
(70% vs 23%; P < .05), popliteal artery occlusion (47.1% vs 14.5%; P < .05)
and the combination of popliteal occlusion with no tibial runoff (29.4% vs
4.4%, P < .05) were each associated with BKA failures. Arterial duplex
data was available for 32 (28%) of the healed BKAs and six (23%) of the
BKAs to AKA revisions. Peak systolic velocities were signiﬁcantly lower
and below normal thresholds in the BKA failures at the external iliac artery
(P < .05), common femoral artery (P < .05), distal superﬁcial femoral artery
(P < .05), and popliteal artery (P < .05). Median survival was not signiﬁ-
cantly different between the two groups (4.0 vs 3.1 years).
Conclusions: Patients requiring a BKA to AKA revision have identiﬁ-
able risk factors that could be used to predict healing at a particular level and
obviate additional morbidity from subsequent revisions. Long-term survival
does not appear to be negatively impacted by amputation revisions.
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Objectives: While cilostazol is commonly used as an adjunct
following peripheral vascular interventions (PVI), its efﬁcacy remains uncer-
tain. We assessed the effect of cilostazol on outcomes following PVI using
meta-analytic techniques.Methods: We searched MEDLINE (1946-2012), Cochrane
CENTRAL (1996-2012), and trial registries for studies comparing cilosta-
zol in combination with antiplatelet therapy to antiplatelet therapy alone
following PVI. Treatment effects were reported as pooled risk/hazard ratios
using random effects models.
Results: Two randomized trials and four retrospective cohort studies
met inclusion criteria (total n ¼ 1522). Across studies, mean age ranged
from 66-76 years, the majority of patients were male (59%-82%), and
mean follow-up ranged from 18-37 months. Pooled estimates demonstrated
that the addition of cilostazol was associated with decreased restenosis (RR,
0.71; 95% CI, 0.60-0.84; P < .001,), improved amputation-free survival
(HR, 0.63; 95% CI, 0.47-0.85; P ¼ .002), improved limb salvage (HR,
0.42; 95% CI, 0.27-0.66; P < .001), and improved freedom from target
lesion revascularization (RR, 1.36; 95% CI, 1.14-1.61; P < .001) (Fig).
There was no signiﬁcant reduction in mortality among those receiving cil-
ostazol (RR, 0.73; 95% CI, 0.45-1.19; P ¼ .21).
Conclusions: The addition of cilostazol to standard therapy following
PVI is associated with a reduced risk of restenosis, amputation and target
lesion revascularization in our meta-analysis of six studies. Consideration
of cilostazol as a medical adjunct after PVI is warranted, presuming these
ﬁndings are broadly generalizable.
Fig.
Contemporary Outcomes of Endovascular vs Surgical Revascula-
rization for Acute Limb Ischemia (ALI)
Ashraf Taha, Efthimios Avgerinos, Luke Marone, Raphael Byrne, Larry
Fish, Michel Makaroun, Rabih A. Chaer. UPMC, Pittsburgh, Pa
Objectives: The purpose of this study was to compare contemporary
endovascular with surgical revascularization for ALI.
Methods: Consecutive patients with ALI treated with endovascular
(ER) or surgical revascularization (OR) between 2005 and 2011 were
identiﬁed and reviewed. Procedural success and outcomes were com-
pared between the two groups. Limb salvage and survival were assessed
using time-to-event methods, including Kaplan-Meier estimation and
competing-risks regression models.
Results: One-hundred ﬁfty-four limbs were treated in 147 patients
in the ER group, compared with 330 limbs in 296 patients in the OR
group. Patient characteristics, severity of ischemia, and indications for
intervention are presented in the Table. The mean follow-up was 14
months. Overall technical success was achieved in 80.5% (ER) vs 88.6%
(OR) (P ¼ .019). Thirty-day mortality rate was 5.4% (ER) and 13.2%
(OR) (P ¼ .013). Amputation rates were 6.5% (ER) vs13.3% (OR) at 30
days (P ¼ .027), and 13.0% (ER) and 19.7% (OR) at 1 year (P ¼ .075).
The primary patency was 57% (ER) and 53% (OR) at 1 year (P ¼ .301).
Rutherford class 2 ischemia represented the majority of our patients,
where overall technical success was 79.9% (ER) vs 91.5% (OR) (P ¼ .001).
Technical success in this class was higher with OR when performed for
a failed bypass (94.7% OR vs 75% ER; P ¼ .001), but with similar 1-year
amputation rates (25.0% OR vs 23.1% ER; P ¼ .84). Technical success was
comparable between the two groups for patients treated for embolic ALI
or in situ thrombosis, as were the amputation rates at 30 days and 1 year (P
¼ NS). Predictors of limb loss by life table analysis included coronary
artery disease (SHR ¼ 2.24; P ¼ .005) and end stage renal disease/dialysis
(SHR ¼ 2.76; P ¼ .031). Predictors of death by life table analysis included
age (SHR ¼ 1.02; P ¼ .001), end-stage renal disease (SHR ¼ 5.67; P <
.001), cancer (SHR ¼ 1.48; P ¼ .02), and rhabdomyolysis (SHR ¼ 3.07;
P < .01).
Conclusions: Patients presenting with Rutherford class 2 ALI are
commonly treated with endovascular or surgical revascularization with
